Literature DB >> 28127941

Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.

J M Tait1, H Wang2, B P Stephens1, M Miller1, P G McIntyre1, S Cleary2, J F Dillon1.   

Abstract

Successful hepatitis C virus (HCV) therapy depends on effective pathways of care. Over two decades, we have developed four sequential models of care latterly using a multidisciplinary managed care network to improve HCV testing, care and treatment. This was a cohort study to evaluate the effectiveness of care pathways, carried out using all HCV antibody-positive individuals tested in a geographical region between 1994 and 2014. The study involved 3122 HCV-positive patients. They were divided into four subgroups representing different care pathways defined by their date of HCV antibody diagnosis. The number who accessed treatment services within 1 year of diagnosis increased from 77 of 292 (26.3%) to 521 of 821 (72.9%). The rate of treatment starts within 1 year of diagnosis increased from 6 of 292 (2.0%) to 133 of 821 (16.2%), and the sustained viral response rate improved from 61.6% to 77.4%. All-cause mortality decreased from 232 of 688 (33.7%) in subgroup A to 55 of 1207 (4.5%) in subgroup D, and multivariate analysis showed that pathway type was an independent predictor of mortality irrespective of age, sex, SVR status or HIV co-infection with pathway in D having an odds ratio of 0.53(0.40-0.77; P<.001) compared to pathway in A. At study end, 78% (3122) of an estimated 4000 HCV positive had been diagnosed. In total, 97.5% of HCV caseload was referred to specialist services and 89% attended for assessment. The introduction of a managed care network increased access to care and reduced all-cause mortality.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  access to care; hepatitis C virus; managed care networks; people who inject drugs; sustained viral response

Mesh:

Year:  2016        PMID: 28127941     DOI: 10.1111/jvh.12633

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  2 in total

1.  Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.

Authors:  Andrew Radley; Marijn de Bruin; Sarah K Inglis; Peter T Donnan; John F Dillon
Journal:  BMJ Open       Date:  2018-12-14       Impact factor: 2.692

2.  Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.

Authors:  A J Wade; J S Doyle; E Gane; C Stedman; B Draper; D Iser; S K Roberts; W Kemp; D Petrie; N Scott; P Higgs; P A Agius; J Roney; L Stothers; A J Thompson; M E Hellard
Journal:  Trials       Date:  2018-07-16       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.